期刊
CLINICAL NUCLEAR MEDICINE
卷 48, 期 12, 页码 1078-1081出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004843
关键词
Ac-225; bone metastases; metastatic castration-resistant prostate cancer; PSMA
This article presents a case of castration-resistant prostate cancer with multiple bone metastases, where remission of clinical symptoms and imaging lesions were observed after 4 cycles of Ac-225-PSMA-617 therapy, with no observable adverse effects.
Lu-177-prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer has emerged as a very promising therapy. However, some of the PSMA-expressing positive metastatic castration-resistant prostate cancer patients never respond or develop resistance to Lu-177-PSMA. We present a case of castration-resistant prostate cancer with multiple bone metastases. Remission of clinical symptoms and imaging lesions can be observed after 4 cycles of Ac-225-PSMA-617 therapy. Moreover, the man did not have any observable adverse effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据